Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?
Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach. Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia [...]
Research by Drs. Alexander Taylor and Stephanie Skala seek to understand why tumors masquerade as forms of type-2 papillary of renal cell carcinoma. The study was just published in Urologic Oncology's ScienceDirect [...]
Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments – and wildly different outcomes for patients as a result. By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers from the University of Michigan Rogel Cancer Center have identified the cells [...]
A research effort by Drs. Jolanta Grembecka and Tomasz Cierpicki was just published in Nature Communications. Learn more about the protein made by the ASH1L gene, which plays a key role in the development of acute leukemia, along with other diseases [...]
Research from the Department's Lombard Lab was just published in the Journal of Clinical Investigation. The study, which focuses on how the deacylase SIRT5 compound supports melanoma viability by influencing chromatin dynamics, was led by Dr. Lombard [...]
Congratulations to Arul Chinnaiyan, MD, PhD, who was announced as the Science of Oncology Award and Lecture recipient by the American Society of Clinical Oncology (ASCO). As part of this award, Chinnaiyan will present a 30-minute lecture entitled “Exploring Precision Oncology: from Gene Fusions to Related Genetic Drivers“ at the ASCO Annual Meeting, to be held virtually on June 4-8, 2021 [...]
A new publication from the Department of Pathology, led by Dr. Kathleen Cho, was just published in the American Association for Cancer Research's flagship journal. highlights how altering the microbiome within a mouse model of oviductal high-grade serious carcinoma can inhibit tumorigeneis [...]
MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.
Dr. Mehra discusses his career path and how he arrived at Michigan Medicine in our latest Careers in Pathology video.
A collaboration between the Department of Pathology and the Department of Dermatology examined biomarkers of outcomes in 346 cases of Merkel cell carcinoma (MCC), an aggressive type of skin cancer. The study was published in the recent edition of Clinical Cancer Research [...]
A new publication, generated by Department of Pathology faculty members Drs. Aaron Udager and Scott Tomlins was successfully published in European Urology. The research highlights a longitudinal cohort study centered around the serial molecular profiling of low-grade prostate cancer in order to better assess tumor upgrading [...]
A new study by the University of Michigan's Rogel Cancer Center analyzed patients with cancer and the factors that cause the cancer to spread to the liver, leading to worse outcomes.
Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus. wo proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, MD, PhD. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers [...]
A new study led by Drs. Jolanta Grembecka and Tomasz Cierpicki of the Department of Pathology was just published in Blood's American Society of Hematology. The research focuses on combinatorial treatment with menin and FLT3 and how inhibitors induce complete remission in acute myeloid leukemia (AML) with activating FLT3 mutations [...]
Congratulations to Dr. Thomas Giordano and the entire Cancer Genome Atlas Project team for winning the American Association of Cancer Research's 2020 Team Science Award [...]
Congratulations to Dr. Celina Kleer who was awarded the American Society for Investigative Pathology (ASIP)'s 2020 Outstanding Investigator Award. Dr. Kleer receives the award for her demonstrated excellence in research in experimental pathology [...]
10:00 am EST
Join us for a virtual event featuring the Department of Pathology's Dr. Celina Kleer, who will host a discussion related to her experiences in understanding breast cancer and her journey as a physician-scientist.
Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family, whose malfunction is associated with several types of cancer.
In a new study, Chan Chung et al. from the Venneti laboratory have discovered a “catch 22”-like phenomena, where epigenetic and metabolic pathways feed one another, in a childhood brain tumor called Diffuse Intrinsic Pontine Gliomas (DIPG) [...]
Dr. Celina Kleer named 2019 AACR Outstanding Investigator in Breast Cancer Research
The research was just published in Modern Pathology and highlights the importance of next-generation sequencing within oncogenic roles for P53 and JAK/STAT signaling in microcystic adnexal carcinomas.
The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.
The research, which focuses on invasive squamous cell carcinomas and the precursor lesions that demonstrate concordic genomic complexity in driver genes, was just published in Modern Pathology.
Marcin Cieslik, Assistant Professor of Pathology and Computational Medicine and Bioinformatics and member of the Michigan Center for Translational Pathology (MCTP), received an award from Bristol-Myers Squibb (BMS) for the project entitled, “Identification of novel therapeutic vulnerabilities across immunophenotypes of refractory and metastatic tumors.” This award provides two years of funding.
A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.
January is Cervical Health Awareness Month. While cervical health is important twelve months of the year, it’s a great time to schedule necessary appointments and screenings. According to Dr. Richard Lieberman, with regular health screenings and the use of pap-smear testing, death rates from cervical cancer have dropped 90% since 1943. [...]
Chan Chung, PhD, received two grants in funding from the ChadTough Foundation and Defeat DIPG foundation ($150,000) and the Robert Connor Dawes CERN Pediatric Fellowship ($100,000). [...]
The National Cancer Institute’s (NCI) Predoctoral to Postdoctoral Fellow Transition (F99/K00) Award supports outstanding PhD and other Research Doctoral candidates who complete their dissertation research training (F99 phase) and transition in a timely manner to mentored, cancer-focused postdoctoral career development research positions (K00 phase). [...]
The American Association for Cancer Research announced that Celina Kleer, MD, the Harold A. Oberman Collegiate Professor of Pathology and Director of the Breast Pathology Program, will be the recipient of the 2019 Outstanding Investigator in Breast Cancer Research, supported by the Breast Cancer Research Foundation.
Speaking directly with a pathologist could help patients better understand their diagnosis and feel empowered, a survey of patient sentiment finds.
Surinder Kumar, Ph.D., has received The Pablove Foundation Childhood Cancer Research Grant for his proposal entitled “The sirtuin SIRT5 as a novel therapeutic target for Ewing’s Sarcoma” [...]
Every year in the United States, nearly 3 million men hear the words, “You have prostate cancer.” That is 1 in 9 men each year. The word “cancer” triggers an immediate response in most people…fear, worry about family, denial, and often an increased awareness of one’s mortality. [...]